A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

The promising drug combination was discovered and tested by Karuna Therapeutics, which Bristol Myers Squibb acquired in March. Bristol Myers Squibb will sell the drug combination under the brand name ...

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...

The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion. This is the first new class of treatment for the psychiatric disorder since ...

The funding aims at supporting further advancements on the Coventry-based firms technology platform to accelerate the development of biologic therapeutics. Funding was co-led by BGF, Octopus ...

Actress Karuna Pandey, known for her role in Pushpa Impossible, shares her journey from learning Bharatnatyam and Kathak to pursuing a degree in Performing Arts. Despite the pressures of social ...

Teachers' Day celebrates educators' pivotal role in shaping futures. Artists recount how their teachers profoundly impacted their lives and careers. They highlight lessons of independence ...

Mayank Mamtani, an analyst from B.Riley Financial, reiterated the Buy rating on Denali Therapeutics (DNLI – Research Report). The associated price target remains the same with $33.00.